Scroll long enough through summer content and you will find it: before-and-after clips of deep, even tans with no beach in sight, credited to “tanning peptides”, nasal sprays or tiny injections. The compound behind most of these posts is Melanotan II, usually shortened to MT2. It has a real scientific history and a genuinely interesting mechanism. It also has a set of risks that rarely make it into the captions.

Where MT2 came from

MT2 began as a cancer-prevention idea. In the 1980s and 1990s, researchers at the University of Arizona set out to make a synthetic version of alpha-melanocyte-stimulating hormone (alpha-MSH), the hormone that tells skin cells to make pigment. The goal was a “sunless tan” that could protect fair-skinned people from UV damage and skin cancer.

Natural alpha-MSH breaks down in minutes, so the team engineered more stable analogues. Melanotan I (now called afamelanotide) was one. Melanotan II was another: a smaller, ring-shaped (cyclic) seven-amino-acid peptide that proved far more potent.

How it works

Pigment cells in the skin, called melanocytes, carry a receptor named MC1R. When alpha-MSH or a mimic like MT2 binds it, melanocytes produce more eumelanin, the brown-black pigment behind a tan. In a small 1996 pilot study, MT2 darkened skin in volunteers without sun exposure.

The catch is that MT2 is not selective. It also activates MC3R and MC4R, receptors in the brain involved in appetite and sexual function. That explains its best-known side effects: nausea, facial flushing, reduced appetite and, in men, spontaneous erections. That last effect was striking enough that researchers developed a related compound, bremelanotide, which the FDA later approved in 2019 to treat low sexual desire in premenopausal women.

The safety picture

MT2 has never been approved as a medicine in any country, and regulators including the US FDA, the UK’s MHRA and Australia’s TGA have warned consumers against unlicensed melanotan products. The concerns fall into three groups:

Mole changes. Dermatology journals have published case reports of new moles, darkening moles and changes in existing moles in people using unlicensed melanotan, along with a small number of melanoma diagnoses. Causation has not been proven, but stimulating pigment cells across the whole body is exactly the kind of exposure dermatologists want to be cautious about.

Unknown products. Online tanning products are frequently unlabelled, untested and of unknown purity or dose.

No long-term data. There are no large, long-term human safety studies.

There is a useful contrast here. Afamelanotide, the more selective sibling, went through full clinical trials and won FDA approval in 2019 as Scenesse, an implant for erythropoietic protoporphyria, a rare condition that makes sunlight painful. The difference between an approved drug and a social media trend is precisely those trials.

Why researchers still study it

In the lab, MT2 peptide remains a valuable tool for studying the melanocortin system: how pigmentation is controlled, how MC4R shapes appetite and energy balance, and how these receptors influence behaviour. Research-grade MT2 is supplied for exactly that kind of laboratory work, not for personal tanning.

Skin-focused peptide research worth watching

If peptides and skin interest you, the more grounded story is copper peptide research. GHK-Cu is a naturally occurring copper-binding tripeptide found in human plasma, and its levels decline with age. Cell studies show it stimulates collagen and glycosaminoglycan production in skin fibroblasts, and it has been used in topical cosmetic formulations for years. Laboratories studying skin remodelling use research-grade GHK-Cu peptide to explore those pathways.